Literature DB >> 11418697

A retro-inverso peptide mimic of CD28 encompassing the MYPPPY motif adopts a polyproline type II helix and inhibits encephalitogenic T cells in vitro.

M Srinivasan1, R M Wardrop, I E Gienapp, S S Stuckman, C C Whitacre, P T Kaumaya.   

Abstract

Complete activation of T cells requires two signals: an Ag-specific signal delivered via the TCR by the peptide-MHC complex and a second costimulatory signal largely provided by B7:CD28/CTLA-4 interactions. Previous studies have shown that B7 blockade can either ameliorate experimental autoimmune encephalomyelitis by interfering with CD28 signaling or exacerbate the disease by concomitant blockade of CTLA-4 interaction. Therefore, we developed a functional CD28 mimic to selectively block B7:CD28 interactions. The design, synthesis, and structural and functional properties of the CD28 free peptide, the end group-blocked CD28 peptide, and its retro-inverso isomer are shown. The synthetic T cell-costimulatory receptor peptides fold into a polyproline type II helical structure commonly seen in regions of globular proteins involved in transient protein-protein interactions. The binding determinants of CD28 can be transferred onto a short peptide mimic of its ligand-binding region. The CD28 peptide mimics effectively block the expansion of encephalitogenic T cells in vitro suggesting the potential usefulness of the peptides for the treatment of autoimmune disease conditions requiring down-regulation of T cell responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418697     DOI: 10.4049/jimmunol.167.1.578

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Allogenic donor splenocytes pretreated with antisense peptide against B7 prolong cardiac allograft survival.

Authors:  J Chen; Q He; R Zhang; Y Chu; Y Wang; Q Liu; S Xiong
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

3.  HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.

Authors:  Megan Jo Miller; Kevin C Foy; Jay P Overholser; Rita Nahta; Pravin Tp Kaumaya
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

4.  IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.

Authors:  Kevin Chu Foy; Megan J Miller; Jay Overholser; Siobhan M Donnelly; Rita Nahta; Pravin Tp Kaumaya
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

5.  Novel p65 binding glucocorticoid-induced leucine zipper peptide suppresses experimental autoimmune encephalomyelitis.

Authors:  Mythily Srinivasan; Srihari Janardhanam
Journal:  J Biol Chem       Date:  2011-09-29       Impact factor: 5.157

Review 6.  Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Authors:  Pravin T P Kaumaya; Kevin Chu Foy
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

7.  Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo.

Authors:  Kevin C Foy; Zhenzhen Liu; Gary Phillips; Megan Miller; Pravin T P Kaumaya
Journal:  J Biol Chem       Date:  2011-02-16       Impact factor: 5.157

8.  Retro-inverso D-peptides as a novel targeted immunotherapy for Type 1 diabetes.

Authors:  Angela Lombardi; Erlinda Concepcion; Hanxi Hou; Hanane Arib; Mihaly Mezei; Roman Osman; Yaron Tomer
Journal:  J Autoimmun       Date:  2020-09-17       Impact factor: 7.094

Review 9.  Role of co-stimulation in Leishmaniasis.

Authors:  Rashmi Tuladhar; Gayathri Natarajan; Abhay R Satoskar
Journal:  Int J Biol Sci       Date:  2011-11-01       Impact factor: 6.580

10.  Proline rich motifs as drug targets in immune mediated disorders.

Authors:  Mythily Srinivasan; A Keith Dunker
Journal:  Int J Pept       Date:  2012-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.